Agent-based modeling demonstrates how target-independent processes supplement killing by antibody-drug conjugates in cancer therapy
Fig 4
Experimental and simulated efficacy of ADCs in immunocompetent mice.
To capture the activation of immune cells following ADC treatment, the percentage of active T cells in the model was increased from 10% (untreated) to 18% (EphA2-Tubulysin) or 22% (EphA2-PBD) based on values reported in Rios-Doria et al. [8]. While only measured for one dose of each ADC (5 mg/kg for EphA2-Tubulysin and 0.3 mg/kg for EphA2-PBD), these values were kept constant across doses. Error bars represent standard deviation; each simulation point is the result of 300 simulation runs (100 simulations run in triplicate).